Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy
Authors:
Open Access
- 1 March 2016
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 56, 122-130
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 studyThe Lancet Oncology, 2015
- Mode of action of trabectedin in myxoid liposarcomasOncogene, 2013
- Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewBMC Cancer, 2013
- Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma CellsNeoplasia, 2011
- A Review of Trabectedin (ET-743): A Unique Mechanism of ActionMolecular Cancer Therapeutics, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Translocation-Related SarcomasSeminars in Oncology, 2009
- Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of actionEuropean Journal of Cancer, 2001
- Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Journal of Clinical Oncology, 1995
- Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.Journal of Clinical Oncology, 1993